• Best stocks to buy now
  • Contact
  • Disclaimer
Saturday, May 28, 2022
No Result
View All Result
  • ItalianoItaliano
Best Stocks
  • News
  • Best stocks to buy nowHOT
    Best Stock To Buy Now May 13, 2022

    Best Stocks To Buy Now: Friday, May 27, 2022

    Best Stocks To Buy Now May 24,2022

    Best Stocks To Buy Now: Thursday, May 26, 2022.

    Best Stocks To Buy Now May 26

    Best Stock To Buy Now: Fourthy, 25 May 2022

    Trending Tags

    • BABA
    • DIS
    • TSLA
    • SKLZ
    • NYSE: GME
  • Categories
    • Crypto
    • Dow Jones Today
    • Pre-IPO and Startups
    • Tech Stocks
    • Utility Stocks
  • Data & Tools
    • Indices
    • Portfolio Tracker
    • Stock Quotes
    • Stock Targets
  • About us
  • News
  • Best stocks to buy nowHOT
    Best Stock To Buy Now May 13, 2022

    Best Stocks To Buy Now: Friday, May 27, 2022

    Best Stocks To Buy Now May 24,2022

    Best Stocks To Buy Now: Thursday, May 26, 2022.

    Best Stocks To Buy Now May 26

    Best Stock To Buy Now: Fourthy, 25 May 2022

    Trending Tags

    • BABA
    • DIS
    • TSLA
    • SKLZ
    • NYSE: GME
  • Categories
    • Crypto
    • Dow Jones Today
    • Pre-IPO and Startups
    • Tech Stocks
    • Utility Stocks
  • Data & Tools
    • Indices
    • Portfolio Tracker
    • Stock Quotes
    • Stock Targets
  • About us
No Result
View All Result
Best Stocks
Home News

Accolade stock: Q3 2022 earnings beat expectations

by Roberto Liccardo
January 10, 2022
in News
0
Accolade-stock-Q3-2022-earnings
21
SHARES
167
VIEWS
Share on FacebookShare on Twitter

A few minutes earlier, at 4:30 PM ET, Accolade (NASDAQ: ACCD) reported their Q3 2022. The company – now trading at $19.37, with a -64.67% decrease in price in the last six months – has beaten the EPS Estimated and the Revenue Estimated. The Actual EPS reported is -$0.31 against the -$0.63 estimated and with Revenue during the quarter of $83.5M against an estimated $75.89M (+97.4% Y/Y).

During the earnings call, the company provided a preliminary forecast for the fiscal year 2023, anticipating a 25% increase in sales.

The company has constantly missed the EPS Estimated during the last three earnings reports with a -12.64% surprise on Q2 2022, reported on Oct 7th. On the other side, Accolade has beaten the Expected Revenues during the last three earning reports exceeding expectations by 4.15% during the Q2 2022.

During the Q3 2022 earnings call, the management highlighted an effort to acquire more clients in Accolade Care virtual primary care and launch in full-scale Accolade One, a full-service offering. In addition, Singh, the CEO, highlighted how the company’s customized health care solutions approach is the key to the next generation of health care services.

ACCD that went public on July 2nd, 2020, has lost over 64% in the last six months, trading $19.38 at market close. After posting Q3 2022, Accolade stock is up by 13.38% in post-market trading.

Contents hide
1 The Accolade mission
2 Personalizing healthcare

The Accolade mission

Accolade aims to make healthcare more personalized for employers and employees.

Their goal is to improve healthcare outcomes by providing more tailored care focused on what people need. Accolade has three different offerings, mainly targeting companies rather than individuals.

The first is the Disease Management Program which consists of an annual physical evaluation for employees, plus customized interventions if they are found to have an illness. The second is the Health Risk Assessment Program which helps employees take charge of their health by identifying risks and providing prevention tips. And finally, the Wellness Program offers small group classes in yoga, strength training, and career coaching to put employees in the best position possible to succeed in all aspects of life.

Accolade is an innovative healthcare company founded on the idea of personalized care. They believe that each person is unique and deserves to be treated as such. That’s why Accolade offers a range of options for personalized healthcare. From cosmetic surgery for men and women to weight loss programs, Accolade has it all.

Personalizing healthcare

Accolade shows that personalized healthcare is an achievable goal that aims to diagnose and treat each individual with care tailored to their unique needs. This often includes genetic testing, psychotherapy, or medical devices.

Personalized healthcare is the next frontier in medicine. 

Personalized medicine has already improved the way we diagnose and treat disease. The health care industry is rapidly changing to meet the needs of a digital, data-driven world. For example, hospitals use phenotyping to design better-personalized treatments for patients, while doctors administer cancer treatments based on genetic information previously impossible to collect or analyze. 

These are just some ways that personalized healthcare is helping us live healthier lives. With the digitization of our lives, doctors are designing more personalized treatments for patients by collecting data and delivering it back to them. 

In general, healthcare stocks are still a popular investment option, as they are seen as less volatile than other sectors. It’s also believed that the aging population will continue to place increasing demand on healthcare services. The healthcare industry is a multi-trillion dollar industry that continues to grow. Healthcare costs are rising, and the need for high-quality care is increasing. 

Tags: ACCD Q3 2022Accolade earningsAccolade Q3 2022
Roberto Liccardo

Roberto Liccardo

Roberto holds a Master's Degree in Communication and proudly wears his 15 years of direct and managerial experience in intensive Digital Marketing and Financial Analytics. He was the founder of Good Noon, a Digital Marketing Agency awarded by Expertise among the top 10 best marketing agencies in San Francisco in 2020.

Latest

AMC-News

AMC Stock Gains Big On Market Rebound

14 hours ago
Rosneft Oil Co Stock

Rosneft Oil Co and Others Exits Market: Smaller Firms Takes Advantage

16 hours ago

Popular News

  • AMZN Stock Forecast

    Amazon Stock Forecast And Price Prediction (Updated May 2022)

    17 shares
    Share 0 Tweet 0
  • Tesla Stock: Buy Now Or After Split?

    15 shares
    Share 0 Tweet 0
  • Stocks to buy now – April 2nd, 2022

    16 shares
    Share 0 Tweet 0
  • What and how to research before you begin forex trading

    15 shares
    Share 0 Tweet 0
  • The Chick Fil A Stock Price and Net Worth: The Company and Its Value

    28 shares
    Share 0 Tweet 0

Free Stocks Recommendations

Get notified everytime we recommend a stock.
Marketing by

DISCLAIMER

Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.

The Best Stocks, its managers, its employees, affiliates and assigns (collectively “The Company”) do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.

READ MORE

Follow us on Social Media
Facebook – YouTube – Twitter

Write for us
Finance – Business

Best-Stocks-Logo_dark

Categories
Best Stocks to buy now
Crypto
Dow Jones Today
Pre-IPO and Startups
Tech stocks
Utility Stocks

Data and Tools
Quote
Target
Wealth
Converter
Dow Jones Today

Best Stocks to Buy Now

We are a financial media dedicated to providing stock recommendations, news, and real-time stock prices.

Newsletter

Get free stock recommendations and real-time news. Our portfolio has returned over 100% in 2020.

Marketing by
  • Disclaimer
  • Best stocks to buy now
  • Contact
  • Write for us – Finance, Crypto

© 2022 Best Stocks

No Result
View All Result
  • Home
  • News
  • Best stocks to buy now
  • Categories
    • Crypto
    • Dow Jones Today
    • Pre-IPO and Startups
    • Tech stocks
    • Utility Stocks
  • Data & Tools
    • Indices
    • Portfolio Tracker
    • Stock Quotes
    • Stock Targets
  • About us
  • English
  • Italiano

© 2022 Best Stocks